DAFTAR PUSTAKA


Anton C, et al. (2012). A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. *CLINICAL SCIENCE* (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Obstetrics and Gynecology, São Paulo/SP, Brazil), 437-41.


Chen WT, et al. (2014). HE4 as a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer. *Asian Pacific Journal of Cancer Prevention* (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center


6. Jakarta; Epidemiologi Indonesia


Moore RG, et al. (2012). Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *American Journal of Obstetrics & Gynecology* (Department of Obstetrics and Gynecology, and the Department of Pathology and Laboratory Medicine (Dr Steinhoff), Women and Infants Hospital, Alpert Medical School of Brown University, Providence), 351.e1-e8.


Tanamas G, et al. (2014). Risk of Malignancy Index is not accurate as a Triage Tool for Ovarian Cancer. *Indones J Obstet Gynecol* (Division of Oncology Gynecology Department of Obstetrics and Gynecology Faculty of Medicine University of Indonesia/ Dr. Cipto Mangunkusumo Hospital, Jakarta), 51-4.


Watcharada M and Pissamai Y. (2009). The Risk of Malignancy Index (RMI) in Diagnosis of Ovarian Malignancy. *Asian Pacific Journal of Cancer Prevention* (Department of Obstetrics and Gynecology, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Thailand), 865-68.


